{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:37:36Z","timestamp":1791221856871,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7266,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,2]]},"DOI":"10.1023\/a:1008360118617","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"177-181","source":"Crossref","is-referenced-by-count":36,"title":["Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer"],"prefix":"10.1016","volume":"11","author":[{"given":"M.","family":"Orlando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Salum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.R.","family":"Chac\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008360118617_bb0005","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3322\/canjclin.47.4.239","article-title":"An adjustment to the 1997 estimate for new prostate cancers","volume":"47","author":"Wingo","year":"1997","journal-title":"CA Cancer J Clin"},{"key":"10.1023\/A:1008360118617_bb0010","series-title":"Cancer: Principles and Practice of Oncology","first-page":"1363","article-title":"Cancer of the prostate","author":"Oesterling","year":"1997"},{"key":"10.1023\/A:1008360118617_bb0015","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/JCO.1997.15.1.382","article-title":"Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm","volume":"15","author":"Small","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0020","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.1999.17.10.3160","article-title":"Vinblastine versus vinblastine plus estramustine phosphate for patients with hormone refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial","volume":"17","author":"Hudes","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0025","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.1995.13.9.2208","article-title":"Prospective evaluation of hidrocortisone and suramin in patients with androgen-indipendent prostate cancer","volume":"13","author":"Kelly","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0030","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1200\/JCO.1997.15.9.3156","article-title":"Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer","volume":"15","author":"Hudes","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0035","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/1097-0142(197008)26:2<249::AID-CNCR2820260202>3.0.CO;2-7","article-title":"Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate","volume":"26","author":"Blackard","year":"1970","journal-title":"Cancer"},{"key":"10.1023\/A:1008360118617_bb0040","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0022-5347(17)53502-8","article-title":"Bioavailability, distribution and pharmacokinetics of diethylstilbestrol produced from stilphostrol","volume":"128","author":"Abramson","year":"1982","journal-title":"J Urol"},{"key":"10.1023\/A:1008360118617_bb0045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnci\/88.12.779","article-title":"How much can we rely on the level of prostate-specific antigen as an end-point for evaluation of clinical trials","volume":"88","author":"Eisenberger","year":"1996","journal-title":"A word of caution! J Natl Cancer Inst"},{"key":"10.1023\/A:1008360118617_bb0050","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/jnci\/91.3.244","article-title":"Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer","volume":"91","author":"Scher","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008360118617_bb0055","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.1994.12.10.2005","article-title":"Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate","volume":"12","author":"Pienta","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0060","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1994.12.4.683","article-title":"Phase II study of ketokonazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer","volume":"12","author":"Sella","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0065","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7","article-title":"A phase II study of high-dose estrogens (diyethylstilbestrol diphosphate) in prostate cancer","volume":"56","author":"Citrin","year":"1985","journal-title":"Cancer"},{"key":"10.1023\/A:1008360118617_bb0070","first-page":"248","article-title":"High-dose fosfestrol in phase I\u2013II trial for the treatment of hormone-resistant prostatic adenocarcinoma","volume":"80","author":"Kattan","year":"1993","journal-title":"Bull Cancer"},{"key":"10.1023\/A:1008360118617_bb0075","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1507\/endocrj.44.527","article-title":"Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist","volume":"44","author":"Kitahara","year":"1997","journal-title":"Endocr J"},{"key":"10.1023\/A:1008360118617_bb0080","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jnci\/88.13.908","article-title":"Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells","volume":"88","author":"Robertson","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008360118617_bb0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0165-7992(85)90086-7","article-title":"Diethylstilbestrol induces metaphase arrest and inhibits microtubule assembly","volume":"143","author":"Hartley-Asp","year":"1985","journal-title":"Mutat Res"},{"key":"10.1023\/A:1008360118617_bb0090","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1200\/JCO.1999.17.3.958","article-title":"Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer","volume":"17","author":"Petrylak","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0095","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.1999.17.6.1664","article-title":"Phase II of oral estramustine, oral etoposide and intravenous paclitaxel in hormone-refractory prostate cancer","volume":"17","author":"Smith","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0100","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end-points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0105","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0110","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1200\/JCO.1995.13.9.2208","article-title":"Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer","volume":"13","author":"Kelly","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008360118617_bb0115","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.1994.12.10.2005","article-title":"Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate","volume":"12","author":"Pienta","year":"1994","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419549018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419549018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/2\/177\/19478192\/11-2-177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:13:42Z","timestamp":1582182822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419549018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["S0923753419549018"],"URL":"https:\/\/doi.org\/10.1023\/a:1008360118617","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}